You are here
Patient Enrollment Completed for Phase 2 AIC Trial
The primary endpoint of the Phase II/III ragweed study will be nasal symptoms scores after the second ragweed season in the late summer and early fall of 2005, with secondary endpoints assessing symptoms, medication use and quality of life in both the first and second year. A blinded interim analysis will be made in late 2004 to assess safety and the appropriateness of commencing a one-year Phase III trial in early 2005.
"The collaboration with UCB has been very effective, with both organizations working diligently to advance our ragweed program," said Dr. Dino Dina, president and CEO of Dynavax. "The rapid enrollment of our ragweed trial, particularly given its size and stringent enrollment criteria, is an early indication of the level of interest that both investigators and patients have in this therapy. We believe that this will translate into a significant market opportunity for an improved treatment for seasonal allergic rhinitis caused by allergy to ragweed."
Source: Dynavax Technologies